PMID- 34257531
OWN - NLM
STAT- MEDLINE
DCOM- 20211223
LR  - 20211223
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Print)
IS  - 1219-4956 (Linking)
VI  - 27
DP  - 2021
TI  - LncRNA LINC-PINT Inhibits Malignant Behaviors of Laryngeal Squamous Cell 
      Carcinoma Cells via Inhibiting ZEB1.
PG  - 584466
LID - 10.3389/pore.2021.584466 [doi]
LID - 584466
AB  - Objective: Laryngeal squamous cell carcinoma (LSCC) belongs to head and neck 
      squamous cell carcinoma (HNSCC), with dismal prognosis. Here, this study aims to 
      disclose the role of LINC-PINT in cancer development, which may contribute to 
      improving the clinical outcomes of LSCC treatment. Methods: LINC-PINT expression 
      in LSCC tissues and in TU-177 and Hep-2 cells was quantified, and subsequently, 
      the association between LINC-PINT and LSCC malignancies was analyzed. 
      pcDNA3.1-LINC-PINT or pcDNA3.1-EZH2 was introduced into Hep-2 and TU-177 cells. 
      qRT-PCR and Western blot analyses examined the levels of proteins related to the 
      AKT/mTOR pathway and their phosphorylated proteins in Hep-2 and TU-177 cells. The 
      viability as well as migration and invasion abilities of Hep-2 and TU-177 cells 
      were determined. Also, the distribution of LINC-PINT in Hep-2 cells was 
      investigated as well as the interplay between LINC-PINT and EZH2. The downstream 
      genes that might interact with EZH2 were screened. Results: LINC-PINT expression 
      was inhibited in LSCC tissues and in Hep-2 and TU-177 cells, whose downregulation 
      was associated with unsatisfactory prognosis. LINC-PINT overexpression suppressed 
      the proliferative, migratory and invasive capacities of Hep-2 and TU-177 cells. 
      LINC-PINT, mainly expressing in nuclei, could enrich EZH2 to silence ZEB1. In 
      Hep-2 and TU-177 cells, the inhibition of LINC-PINT or overexpression of ZEB1 
      could enhance cell proliferation, migration and invasion. The phosphorylated 
      levels of proteins related to the AKT/mTOR pathway were declined in cells with 
      LINC-PINT overexpression, and the levels of these phosphorylated proteins were 
      increased in cells with LINC-PINT inhibition. Conclusion: LINC-PINT enriches EZH2 
      to silence ZEB1 and thus inhibits the proliferative, migratory, and invasive 
      capacities of Hep-2 and TU-177 cells. In addition, LINC-PINT might exert its 
      biological function through the AKT/mTOR pathway.
CI  - Copyright (c) 2021 Yang, Miao, Mao, Xiu, Sun, Pei and Jia.
FAU - Yang, Xianguang
AU  - Yang X
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, China.
FAU - Miao, Susheng
AU  - Miao S
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, China.
FAU - Mao, Xionghui
AU  - Mao X
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, China.
FAU - Xiu, Cheng
AU  - Xiu C
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, China.
FAU - Sun, Ji
AU  - Sun J
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, China.
FAU - Pei, Rong
AU  - Pei R
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, China.
FAU - Jia, Shenshan
AU  - Jia S
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, China.
LA  - eng
PT  - Journal Article
DEP - 20210401
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (ZEB1 protein, human)
RN  - 0 (Zinc Finger E-box-Binding Homeobox 1)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Enhancer of Zeste Homolog 2 Protein/genetics/metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - RNA, Long Noncoding/*genetics/metabolism
MH  - Signal Transduction
MH  - Squamous Cell Carcinoma of Head and Neck/*genetics/pathology
MH  - TOR Serine-Threonine Kinases
MH  - Zinc Finger E-box-Binding Homeobox 1/*genetics/metabolism
PMC - PMC8262191
OTO - NOTNLM
OT  - EZH2
OT  - LINC-PINT
OT  - ZEB1
OT  - invasion
OT  - laryngeal squamous cell carcinoma
OT  - migration
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/07/15 06:00
MHDA- 2021/12/24 06:00
PMCR- 2021/04/01
CRDT- 2021/07/14 07:01
PHST- 2020/07/17 00:00 [received]
PHST- 2021/02/11 00:00 [accepted]
PHST- 2021/07/14 07:01 [entrez]
PHST- 2021/07/15 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
PHST- 2021/04/01 00:00 [pmc-release]
AID - 584466 [pii]
AID - 10.3389/pore.2021.584466 [doi]
PST - epublish
SO  - Pathol Oncol Res. 2021 Apr 1;27:584466. doi: 10.3389/pore.2021.584466. 
      eCollection 2021.